Profile data is unavailable for this security.
About the company
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
- Revenue in USD (TTM)0.00
- Net income in USD-42.59m
- Incorporated2018
- Employees123.00
- LocationAdlai Nortye Ltdc/o Ugland HousePO Box 309GRAND CAYMAN KY1-1104Cayman IslandsCYM
- Phone+1 8 482307430
- Websitehttps://www.adlainortye.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protara Therapeutics Inc | 0.00 | -52.90m | 338.18m | 28.00 | -- | 1.91 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 339.76m | 124.00 | -- | 2.01 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Rezolute Inc | 0.00 | -84.23m | 347.38m | 71.00 | -- | 2.71 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 349.69m | 4.00 | -- | 159.35 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 353.21m | 64.00 | -- | 2.94 | -- | 22.44 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Benitec Biopharma Inc | 0.00 | -46.30m | 354.71m | 19.00 | -- | 1.89 | -- | -- | -1.11 | -1.11 | 0.00 | 5.47 | 0.00 | -- | -- | 0.00 | -34.33 | -79.73 | -35.10 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 354.98m | 123.00 | -- | 44.82 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 356.18m | 25.00 | -- | -- | -- | 380.13 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 358.22m | 299.00 | -- | 1.14 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 359.38m | 56.00 | -- | 1.14 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 362.30m | 16.00 | -- | 2.55 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 362.79m | 305.00 | -- | 0.5861 | -- | 12.80 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Vanda Pharmaceuticals Inc. | 216.11m | -220.47m | 366.47m | 533.00 | -- | 1.12 | -- | 1.70 | -3.74 | -3.74 | 3.67 | 5.54 | 0.3774 | 7.29 | 4.25 | 405,450.30 | -38.51 | -6.49 | -48.99 | -7.64 | 93.96 | 92.12 | -102.02 | -17.46 | 2.38 | -- | 0.0224 | -- | 8.72 | -2.73 | -1,066.53 | -- | -11.08 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 371.24m | 32.00 | -- | 1.43 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 373.05m | 16.00 | -- | 4.43 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 374.39m | 34.00 | -- | 2.96 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Adlai Nortye Ltd's reporting currency: US Dollar USD
0.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 31 Dec 2025 | 34.85k | 0.11% |
| SmartHarvest Portfolios LLCas of 31 Dec 2025 | 15.09k | 0.05% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 11.23k | 0.04% |
| EverSource Wealth Advisors LLCas of 31 Dec 2025 | 4.79k | 0.02% |
| UBS Securities LLCas of 31 Dec 2025 | 1.08k | 0.00% |
| Bessemer Investment Management LLCas of 31 Dec 2025 | 91.00 | 0.00% |
| Citadel Securities LLCas of 30 Sep 2025 | 0.00 | 0.00% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
